Content about Generics

May 8, 2012

University of British Columbia researchers may have found a way to develop universal flu vaccines and eliminate the need for seasonal flu vaccinations, university officials announced Tuesday.

VANCOUVER, British Columbia — University of British Columbia researchers may have found a way to develop universal flu vaccines and eliminate the need for seasonal flu vaccinations, university officials announced Tuesday.

May 8, 2012

Consumption of probiotics is associated with a reduced risk of antibiotic-associated diarrhea, a common adverse effect of antibiotic use, according to a review and meta-analysis of previous studies published in the May 9 issue of JAMA, the Journal of the American Medical Association.

CHICAGO — Consumption of probiotics is associated with a reduced risk of antibiotic-associated diarrhea, a common adverse effect of antibiotic use, according to a review and meta-analysis of previous studies published in the May 9 issue of JAMA, the Journal of the American Medical Association.

May 7, 2012

Pharmaceutical wholesaler H. D. Smith will act as the exclusive supplier of various healthcare products for a buying group that serves independent pharmacies, the company said Monday.

SPRINGFIELD, Ill. — Pharmaceutical wholesaler H. D. Smith will act as the exclusive supplier of various healthcare products for a buying group that serves independent pharmacies, the company said Monday.

May 4, 2012

Kmart is introducing prescription pet medications at its stores, the mass merchandise retail chain said Friday.

HOFFMAN ESTATES, Ill. — Kmart is introducing prescription pet medications at its stores, the mass merchandise retail chain said Friday.

The company said the new program was designed to make it easier for customers to get branded and generic pet drugs and more convenient to shop for the whole family. More than 60% of American households own a pet, and families spent more than $50 billion on their pets in 2011, according to the American Pet Products Association.

May 4, 2012

The number of new drug shortages has been halved as early notifications from manufacturers of potential shortages have increased sixfold, the commissioner of the Food and Drug Administration wrote Thursday.

SILVER SPRING, Md. — The number of new drug shortages has been halved as early notifications from manufacturers of potential shortages have increased sixfold, the commissioner of the Food and Drug Administration wrote Thursday.

May 4, 2012

Generic drug maker Watson Pharmaceuticals has appointed Lisa DeFrancesco as its VP global investor relations, the company said Friday.

PARSIPPANY, N.J. — Generic drug maker Watson Pharmaceuticals has appointed Lisa DeFrancesco as its VP global investor relations, the company said Friday.

Succeeding Patricia Eisenhaur, who will leave the company on June 1, DeFrancesco will report directly to chief communications officer Charles Mayr. She will be responsible for investor relations programs and serve as the company's principal spokeswoman and point of contact with the analyst and investment community.

May 3, 2012

The recent loss of business from a key specialty pharmacy customer and the continued deluge of generic introductions will represent significant challenges for Cardinal Health in fiscal year 2013 as it approaches the year-end of its fiscal 2012, company executives told analysts during a conference call Thursday morning.

DUBLIN, Ohio — The recent loss of business from a key specialty pharmacy customer and the continued deluge of generic introductions will represent significant challenges for Cardinal Health in fiscal year 2013 as it approaches the year-end of its fiscal 2012, company executives told analysts during a conference call Thursday morning.

May 2, 2012

The Food and Drug Administration has approved a generic drug for epilepsy made by Acella Pharmaceuticals, the company said Wednesday.

ATLANTA — The Food and Drug Administration has approved a generic drug for epilepsy made by Acella Pharmaceuticals, the company said Wednesday.

Acella announced the approval of gabapentin oral solution in the 250-mg-per-5-mL strength. The drug is a generic version of Parke Davis' Neurontin.

May 2, 2012

Novartis' generics division has acquired Fougera Pharmaceuticals, the company said Wednesday.

BASEL, Switzerland — Novartis' generics division has acquired Fougera Pharmaceuticals, the company said Wednesday.

Sandoz announced the acquisition of Melville, N.Y.-based Fougera for $1.525 billion in cash. Fougera specializes in generic dermatology drugs, and Sandoz said the acquisition would make it the world's largest company in the space.

May 1, 2012

Generic drug maker Mylan has released a version of a drug used to treat bacterial infections, the company said.

PITTSBURGH — Generic drug maker Mylan has released a version of a drug used to treat bacterial infections, the company said.

Mylan announced the launch of doxycycline hyclate delayed-release tablets in the 150-mg strength. The launch follows a decision by the U.S. District Court for the District of New Jersey that Mylan's product did not infringe patents covering the drug's branded version, Doryx. Warner Chilcott, which markets Doryx, had brought the case.

April 30, 2012

Mylan will be barred from marketing a generic version of a Merck cardiovascular drug until the drug's patent expires, under a court ruling announced Friday.

WHITEHOUSE STATION, N.J. — Mylan will be barred from marketing a generic version of a Merck cardiovascular drug until the drug's patent expires, under a court ruling announced Friday.

Merck said the U.S. District Court for the District of New Jersey ruled against Mylan in two patent infringement suits related to the drugs Zetia (ezetimibe) and Vytorin (ezetimibe and simvastatin). Specifically, the court ruled that a patent covering the drug, RE 42,461, is valid and enforceable and enjoined Mylan from launching until the patents expiration in April 2017.

April 30, 2012

Mylan plans to start selling a generic version of a drug for sleep disorders starting in June 2016, under a deal with Teva announced Monday.

PITTSBURGH — Mylan plans to start selling a generic version of a drug for sleep disorders starting in June 2016, under a deal with Teva announced Monday.

Mylan said it had settled with Teva over the former's generic version of Nuvigil (armodafinil) tablets, a drug used to treat sleepiness related to sleep apnea, narcolepsy and shift work disorder.

April 27, 2012

Two companies have settled with Teva over the latter's efforts to launch a generic version of an emergency treatment for allergic reactions.

NEW YORK — Two companies have settled with Teva over the latter's efforts to launch a generic version of an emergency treatment for allergic reactions.

Under the agreement, involving Mylan and Pfizer's Meridian Medical Technologies subsidiary, Teva will be allowed to launch a generic version of EpiPen (epinephrine) auto-injector in June 2015, assuming it wins approval from the Food and Drug Administration. Mylan Specialty markets the EpiPen, which Meridian manufactures.

April 26, 2012

Watson has announced its intention to acquire Actavis, the company said.

PARSIPPANY, N.J. — Watson has announced its intention to acquire Actavis, the company said.

Following news reports Tuesday that the U.S.-based generic drug maker would acquire Switzerland-based Actavis, Watson announced Wednesday that it would buy the latter for $5.6 billion. News media had reported that the deal would be worth $5.9 billion, while there had been estimates in March that Watson would pay up to $7.3 billion.

April 25, 2012

Sun Pharmaceutical Industries has launched a generic version of a drug used to treat psychiatric disorders, the company said.

MUMBAI, India — Sun Pharmaceutical Industries has launched a generic version of a drug used to treat psychiatric disorders, the company said.

Sun announced the launch of olanzapine tablets in the 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg and 20 mg strengths.

The drug is a generic version of Eli Lilly's Zyprexa, used to treat schizophrenia and bipolar disorder. The branded drug and generic versions had sales of $3.28 billion during the 12-month period ended in January, according to IMS Health.

 

April 24, 2012

Dr. Reddy's Labs has launched a generic version of an Eli Lilly drug used to treat psychiatric disorders, the company said Tuesday.

HYDERABAD, India — Dr. Reddy's Labs has launched a generic version of an Eli Lilly drug used to treat psychiatric disorders, the company said Tuesday.

Dr. Reddy's announced the launch of olanzapine tablets in the 2.5-mg, 5-mg, 7.5-mg, 10-mg and 15-mg strengths.

The drug is a generic version of Zyprexa, used to treat schizophrenia and bipolar disorder. Generic and branded versions of the drug had sales of about $3.28 billion during the 12-month period ended in January, according to IMS Health.

April 24, 2012

Globalization has led to a rapid increase in the drugs and foods arriving on U.S. shores from abroad, a trend that has prompted U.S. regulators to transform their approach.

SILVER SPRING, Md. — Globalization has led to a rapid increase in the drugs and foods arriving on U.S. shores from abroad, a trend that has prompted U.S. regulators to transform their approach.

The Food and Drug Administration released a report Monday detailing its strategies for what it called transforming from a domestic to a global public health agency.

April 24, 2012

Mylan has launched a generic drug for treating psychiatric disorders, the company said Tuesday.

PITTSBURGH — Mylan has launched a generic drug for treating psychiatric disorders, the company said Tuesday.

Mylan announced the launch of olanzapine tablets in the 2.5-mg, 5-mg, 7.5-mg, 10-mg, 15-mg and 20-mg strengths.

The drug, a generic version of Eli Lilly's Zyprexa, is used to treat schizophrenia and bipolar disorder. Various versions of the drug had sales of about $3.3 billion in 2011, according to IMS Health.

April 24, 2012

Watson Pharmaceuticals is buying Actavis Group for $5.9 billion, according to published reports.

NEW YORK — Watson Pharmaceuticals is buying Actavis Group for $5.9 billion, according to published reports.

April 23, 2012

Par Pharmaceutical has bought rights to a generic drug for gastroesophageal reflux disease from Handa Pharmaceuticals, Par said.

WOODCLIFF LAKE, N.J. — Par Pharmaceutical has bought rights to a generic drug for gastroesophageal reflux disease from Handa Pharmaceuticals, Par said.

Handa, based in Fremont, Calif., sold rights to the regulatory approval application it filed with the Food and Drug Administration for dexlansoprazole capsules, a generic version of Takeda's Dexilant, in the 60-mg strength.

April 23, 2012

Watson Pharmaceuticals announced the launch of an authorized generic version of a drug used to lower blood glucose in patients with Type 2 diabetes.

PARSIPPANY, N.J. — Watson Pharmaceuticals announced the launch of an authorized generic version of a drug used to lower blood glucose in patients with Type 2 diabetes.

April 21, 2012

More than 250 executives joined Anda for its 5th Annual Supply Chain Symposium here Thursday and Friday.

PALM BEACH, Fla. — More than 250 executives joined Anda for its 5th Annual Supply Chain Symposium here Thursday and Friday.

(For photos of the event, click here.)

April 20, 2012

According to the latest numbers, the country's economy is slowly growing, while unemployment has been slowly declining. But while growth has been somewhat less than stellar, 10 industries have outpaced the rest of the economy, including generic drugs.

NEW YORK — According to the latest numbers, the country's economy is slowly growing, while unemployment has been slowly declining. But while growth has been somewhat less than stellar, 10 industries have outpaced the rest of the economy, including generic drugs.

April 19, 2012

A trade organization representing generic drug manufacturers announced Thursday its latest solution to the problem of drug shortages.

WASHINGTON — A trade organization representing generic drug manufacturers announced Thursday its latest solution to the problem of drug shortages.

April 19, 2012

Generic drug maker Watson is challenging the patent protection on a drug used to treat Type 2 diabetes.

PARSIPPANY, N.J. — Generic drug maker Watson is challenging the patent protection on a drug used to treat Type 2 diabetes.

Watson said Thursday that it had filed with the Food and Drug Administration for approval of a generic version of Depomed's Glumetza (metformin hydrochloride extended-release tablets) in the 1,000-mg strength.